HBV life cycle and novel drug targets

Hepatology International

Volumn 5, Issue 2, 2011, Pages 644-653

  Grimm, Daniel ^a   Thimme, Robert ^a   Blum, Hubert E ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

HBV life cycle

Indexed keywords

2 AMINO 9 (1 PHOSPHONOMETHOXYCYCLOPROPYLMETHYL)PURINE BIS(PIVALOYLOXYMETHYL) ESTER; ADEFOVIR; ALPHA GLUCOSIDASE INHIBITOR; ALPHA INTERFERON; ANTIVIRUS AGENT; AT 130; BAY 41 4109; CASTANOSPERMINE 6 BUTYRATE; CLEVUDINE; COVALENTLY CLOSED CIRCULAR DNA; DNA; ENTECAVIR; HELIOXANTHIN DERIVATIVE; HEPATITIS B VACCINE; HETEROARYLDIHYDROPYRIMIDINE DERIVATIVE; INTERLEUKIN 29; LAMIVUDINE; N [1 (ALPHA CHLOROBENZYLIDENE) 2 OXO 2 (1 PIPERIDINYL)ETHYL]BENZAMIDE; NITAZOXANIDE; NUC B 1000; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA; PEPTIDE DERIVATIVE; SMALL INTERFERING RNA; TELBIVUDINE; TENOFOVIR; THYMOSIN ALPHA1; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ANXIETY; AUTOIMMUNE DISEASE; CYTOPENIA; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FLU LIKE SYNDROME; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; IMMUNOTHERAPY; IRRITABILITY; LIFE CYCLE; MYALGIA; MYOPATHY; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SEROCONVERSION; SIDE EFFECT; TREATMENT DURATION; VACCINATION; VIRAL CLEARANCE; VIRUS CELL INTERACTION; VIRUS ENTRY;

EID: 79956271873     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-011-9261-3     Document Type: Review

References (93)

1. JL Dienstag 2008 Hepatitis B virus infection N Engl J Med 359 14 1486 1500 18832247 10.1056/NEJMra0801644 1:CAS:528:DC%2BD1cXhtFOru7bL
2. Thimme R, Blum HE. (Therapy of hepatitis B). Praxis (Bern 1994) 2006;95(36):1383-1388 (Pubitemid 44407115)
3. ZF SeegerC, Mason WS. Hepadnaviruses. 5th ed. Philadelphia: Lippincott, Williams and Wilkins; 2007
4. LL Stein R Loomba 2009 Drug targets in hepatitis B virus infection Infect Disord Drug Targets 9 2 105 116 19275699 1:CAS:528:DC%2BD1MXlt1Krtb8%3D
5. S Urban A Schulze M Dandri J Petersen 2010 The replication cycle of hepatitis B virus J Hepatol 52 2 282 284 20056291 10.1016/j.jhep.2009.10.031
6. M Nassal 2008 Hepatitis B viruses: reverse transcription a different way Virus Res 134 1-2 235 249 18339439 10.1016/j.virusres.2007.12.024 1:CAS:528:DC%2BD1cXlslWgu74%3D
7. C Balsano A Alisi 2008 Viral hepatitis B: established and emerging therapies Curr Med Chem 15 9 930 939 18473801 10.2174/092986708783955383 1:CAS:528:DC%2BD1cXnsVyitbs%3D (Pubitemid 351736414)
8. European Association for the Study of the Liver (EASL) 2009 EASL Clinical Practice Guidelines: management of chronic hepatitis B J Hepatol 50 2 227 242 10.1016/j.jhep.2008.10.001
9. YF Liaw JJ Sung WC Chow G Farrell CZ Lee H Yuen T Tanwandee QM Tao K Shue ON Keene JS Dixon DF Gray J Sabbat 2004 Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 15 1521 1531 15470215 10.1056/NEJMoa033364 1:CAS:528:DC%2BD2cXot1Kls7w%3D (Pubitemid 39315319)
10. M Levrero T Pollicino J Petersen L Belloni G Raimondo M Dandri 2009 Control of cccDNA function in hepatitis B virus infection J Hepatol 51 3 581 592 19616338 10.1016/j.jhep.2009.05.022 1:CAS:528:DC%2BD1MXpsFyhs7k%3D
11. RE Randall S Goodbourn 2008 Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures J Gen Virol 89 Pt 1 1 47 18089727 10.1099/vir.0.83391-0 1:CAS:528: DC%2BD1cXns1Wiug%3D%3D
12. N Ank H West SR Paludan 2006 IFN-lambda: novel antiviral cytokines J Interferon Cytokine Res 26 6 373 379 16734557 10.1089/jir.2006.26.373 1:CAS:528:DC%2BD28XltVCjur4%3D (Pubitemid 43856685)
13. KA Stegmann NK Bjorkstrom H Veber S Ciesek P Riese J Wiegand J Hadem PV Suneetha J Jaroszewicz C Wang V Schlaphoff P Fytili M Cornberg MP Manns R Geffers T Pietschmann CA Guzman HG Ljunggren H Wedemeyer 2010 Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection Gastroenterology 138 5 1885 1897 20334827 10.1053/j.gastro.2010.01.051 1:CAS:528:DC%2BC3cXmsFykuro%3D
14. GR Stark IM Kerr BR Williams RH Silverman RD Schreiber 1998 How cells respond to interferons Annu Rev Biochem 67 227 264 9759489 10.1146/annurev. biochem.67.1.227 1:CAS:528:DyaK1cXlsFOmsLo%3D (Pubitemid 28411130)
15. G Dusheiko N Antonakopoulos 2008 Current treatment of hepatitis B Gut 57 1 105 124 17502343 10.1136/gut.2005.077891 1:CAS:528:DC%2BD1cXitVKqt70%3D
16. MD Robek BS Boyd SF Wieland FV Chisari 2004 Signal transduction pathways that inhibit hepatitis B virus replication Proc Natl Acad Sci USA 101 6 1743 1747 14757813 10.1073/pnas.0308340100 1:CAS:528:DC%2BD2cXhsFaqtbw%3D (Pubitemid 38234224)
17. P Bailon A Palleroni CA Schaffer CL Spence WJ Fung JE Porter GK Ehrlich W Pan ZX Xu MW Modi A Farid W Berthold M Graves 2001 Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C Bioconjug Chem 12 2 195 202 11312680 10.1021/bc000082g 1:CAS:528:DC%2BD3MXhtFGlur8%3D (Pubitemid 32235471)
18. HL Janssen M van Zonneveld H Senturk S Zeuzem US Akarca Y Cakaloglu C Simon TM So G Gerken RA de Man HG Niesters P Zondervan B Hansen SW Schalm 2005 Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial Lancet 365 9454 123 129 15639293 10.1016/S0140-6736(05)17701-0 1:CAS:528:DC%2BD2MXhvF2gsQ%3D%3D (Pubitemid 40091801)
19. N Ank SR Paludan 2009 Type III IFNs: new layers of complexity in innate antiviral immunity Biofactors 35 1 82 87 19319850 10.1002/biof.19 1:CAS:528:DC%2BD1MXnsVSmur4%3D
20. SV Kotenko G Gallagher VV Baurin A Lewis-Antes M Shen NK Shah JA Langer F Sheikh H Dickensheets RP Donnelly 2003 IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex Nat Immunol 4 1 69 77 12483210 10.1038/ni875 1:CAS:528:DC%2BD38Xps1eltL8%3D (Pubitemid 36109115)
21. M Mordstein E Neugebauer V Ditt B Jessen T Rieger V Falcone F Sorgeloos S Ehl D Mayer G Kochs M Schwemmle S Gunther C Drosten T Michiels P Staeheli 2010 Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections J Virol 84 11 5670 5677 20335250 10.1128/JVI.00272-10 1:CAS:528:DC%2BC3cXms1aktLc%3D
22. P Sheppard W Kindsvogel W Xu K Henderson S Schlutsmeyer TE Whitmore R Kuestner U Garrigues C Birks J Roraback C Ostrander D Dong J Shin S Presnell B Fox B Haldeman E Cooper D Taft T Gilbert FJ Grant M Tackett W Krivan G McKnight C Clegg D Foster KM Klucher 2003 IL-28, IL-29 and their class II cytokine receptor IL-28R Nat Immunol 4 1 63 68 12469119 10.1038/ni873 1:CAS:528:DC%2BD38Xps1elt7c%3D (Pubitemid 36104710)
23. C Sommereyns S Paul P Staeheli T Michiels 2008 IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo PLoS Pathog 4 3 e1000017 18369468 10.1371/journal.ppat.1000017 (Pubitemid 351631092)
24. NE Pagliaccetti EN Chu CR Bolen SH Kleinstein MD Robek 2010 Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities Virology 401 2 197 206 20303135 10.1016/j.virol.2010.02.022 1:CAS:528:DC%2BC3cXlsFajtbo%3D
25. CM Doyle J Han MG Weigert ET Prak 2006 Consequences of receptor editing at the lambda locus: multireactivity and light chain secretion Proc Natl Acad Sci USA 103 30 11264 11269 16847259 10.1073/pnas.0604053103 1:CAS:528: DC%2BD28XnvValtbk%3D (Pubitemid 44156507)
26. SH Hong O Cho K Kim HJ Shin SV Kotenko S Park 2007 Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells Virus Res 126 1-2 245 249 17451832 10.1016/j.virusres.2007.03.006 1:CAS:528:DC%2BD2sXlsFGrurg%3D (Pubitemid 46726717)
27. TR O'Brien 2009 Interferon-alfa, interferon-lambda and hepatitis C Nat Genet 41 10 1048 1050 19749756 10.1038/ng.453
28. Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, Gordon SC, Marotta P, Vierling JM, Carlos Lopez-Talavera J, Byrnes-Blake K, Fontana D, Freeman J, Gray T, Hausman D, Hunder NN, Lawitz E. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010 (Epub ahead of print)
29. S Kakumu T Ishikawa M Mizokami E Orido K Yoshioka T Wakita M Yamamoto 1991 Treatment with human gamma interferon of chronic hepatitis B: comparative study with alpha interferon J Med Virol 35 1 32 37 1940881 10.1002/jmv. 1890350108 1:STN:280:DyaK38%2FksVCrtg%3D%3D
30. HL Weng BE Wang JD Jia WF Wu JZ Xian PR Mertens WM Cai S Dooley 2005 Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study Clin Gastroenterol Hepatol 3 8 819 828 16234012 10.1016/S1542-3565(05)00404-0 1:CAS:528:DC%2BD2MXhtVWjtLnP (Pubitemid 41116736)
31. Zoulim F, Locarnini S. 2009. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137(5):1593-1608, e1591-e1592
32. JJ Sung JY Lai S Zeuzem WC Chow EJ Heathcote RP Perrillo CL Brosgart MA Woessner SA Scott DF Gray SD Gardner 2008 Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B J Hepatol 48 5 728 735 18329126 10.1016/j.jhep.2007.12.026 1:CAS:528: DC%2BD1cXktVGrtbg%3D
33. GK Lau T Piratvisuth KX Luo P Marcellin S Thongsawat G Cooksley E Gane MW Fried WC Chow SW Paik WY Chang T Berg R Flisiak P McCloud N Pluck 2005 Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N Engl J Med 352 26 2682 2695 15987917 10.1056/NEJMoa043470 1:CAS:528:DC%2BD2MXls1SktL8%3D (Pubitemid 41007823)
34. P Marcellin GK Lau F Bonino P Farci S Hadziyannis R Jin ZM Lu T Piratvisuth G Germanidis C Yurdaydin M Diago S Gurel MY Lai P Button N Pluck 2004 Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351 12 1206 1217 15371578 10.1056/NEJMoa040431 1:CAS:528:DC%2BD2cXns12rsr0%3D (Pubitemid 39296307)
35. RD Fleischer AS Lok 2009 Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B J Hepatol 51 4 787 791 19665816 10.1016/j.jhep.2009.06.011 1:CAS:528:DC%2BD1MXhtFagt7%2FJ
36. Jang JH, Kim JW, Jeong SH, Myung HJ, Kim HS, Park YS, Lee SH, Hwang JH, Kim N, Lee DH. Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy. J Viral Hepat (Epub ahead of print)
37. BK Kim J Oh SY Kwon WH Choe SY Ko KH Rhee TH Seo SD Lim CH Lee 2009 Clevudine myopathy in patients with chronic hepatitis B J Hepatol 51 4 829 834 19615776 10.1016/j.jhep.2009.04.019
38. MF Yuen KH Han SH Um SK Yoon HR Kim J Kim CR Kim CL Lai 2010 Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease Hepatology 51 3 767 776 20091678 10.1002/hep.23462 1:CAS:528:DC%2BC3cXks1Sru7w%3D
39. MF Yuen J Kim CR Kim V Ngai JC Yuen C Min HM Kang BS Shin SD Yoo CL Lai 2006 A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B Antivir Ther 11 8 977 983 17302367 1:CAS:528:DC%2BD2sXhtF2qtrc%3D (Pubitemid 44955173)
40. MF Yuen SH Lee HM Kang CR Kim J Kim V Ngai CL Lai 2009 Pharmacokinetics of LB80331 and LB80317 following oral administration of LB80380, a new antiviral agent for chronic hepatitis B (CHB), in healthy adult subjects, CHB patients, and mice Antimicrob Agents Chemother 53 5 1779 1785 19223649 10.1128/AAC.01290-08 1:CAS:528:DC%2BD1MXlvVGgt70%3D
41. MD Erion PD van Poelje DA Mackenna TJ Colby AC Montag JM Fujitaki DL Linemeyer DA Bullough 2005 Liver-targeted drug delivery using HepDirect prodrugs J Pharmacol Exp Ther 312 2 554 560 15340017 10.1124/jpet.104.075903 1:CAS:528:DC%2BD2MXhsVCnsb4%3D (Pubitemid 40189552)
42. BD Herman I Votruba A Holy N Sluis-Cremer J Balzarini 2010 The acyclic 2, 4-diaminopyrimidine nucleoside phosphonate acts as a purine mimetic in HIV-1 reverse transcriptase DNA polymerization J Biol Chem 285 16 12101 12108 20164190 10.1074/jbc.M109.096529 1:CAS:528:DC%2BC3cXksVGksrk%3D
43. MN Brunelle J Lucifora J Neyts S Villet A Holy C Trepo F Zoulim 2007 In vitro activity of 2, 4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants Antimicrob Agents Chemother 51 6 2240 2243 17371827 10.1128/AAC.01440-06 1:CAS:528:DC%2BD2sXmtlKrt78%3D (Pubitemid 46903127)
44. J Balzarini C Pannecouque L Naesens G Andrei R Snoeck E De Clercq D Hockova A Holy 2004 6-[2-phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines: a new class of acyclic pyrimidine nucleoside phosphonates with antiviral activity Nucleosides Nucleotides Nucleic Acids 23 8-9 1321 1327 15571252 10.1081/NCN-200027573 1:CAS:528:DC%2BD2cXptFeisLw%3D (Pubitemid 39625918)
45. C Babinet H Farza D Morello M Hadchouel C Pourcel 1985 Specific expression of hepatitis B surface antigen (HBsAg) in transgenic mice Science 230 4730 1160 1163 3865370 10.1126/science.3865370 1:CAS:528:DyaL28XivFyisg%3D%3D (Pubitemid 16170002)
46. FV Chisari CA Pinkert DR Milich P Filippi A McLachlan RD Palmiter RL Brinster 1985 A transgenic mouse model of the chronic hepatitis B surface antigen carrier state Science 230 4730 1157 1160 3865369 10.1126/science.3865369 1:CAS:528:DyaL28XivFyjuw%3D%3D (Pubitemid 16170001)
47. D Sun M Nassal 2006 Stable HepG2- and Huh7-based human hepatoma cell lines for efficient regulated expression of infectious hepatitis B virus J Hepatol 45 5 636 645 16935386 10.1016/j.jhep.2006.05.019 1:CAS:528: DC%2BD28XhtVWqtr%2FI (Pubitemid 44466664)
48. MJ Root HK Steger 2004 HIV-1 gp41 as a target for viral entry inhibition Curr Pharm Des 10 15 1805 1825 15180542 10.2174/1381612043384448 1:CAS:528:DC%2BD2cXktV2gtr8%3D (Pubitemid 38647463)
49. P Gripon I Cannie S Urban 2005 Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein J Virol 79 3 1613 1622 15650187 10.1128/JVI.79.3.1613-1622.2005 1:CAS:528:DC%2BD2MXhtFCjtb8%3D (Pubitemid 40459108)
50. J Petersen M Dandri W Mier M Lutgehetmann T Volz F von Weizsacker U Haberkorn L Fischer JM Pollok B Erbes S Seitz S Urban 2008 Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein Nat Biotechnol 26 3 335 341 18297057 10.1038/nbt1389 1:CAS:528:DC%2BD1cXjsVGit7o%3D (Pubitemid 351355128)
51. J Kock HE Blum 2008 Hypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3H J Gen Virol 89 Pt 5 1184 1191 18420796 10.1099/vir.0.83507-0
52. C Rosler J Kock M Kann MH Malim HE Blum TF Baumert F von Weizsacker 2005 APOBEC-mediated interference with hepadnavirus production Hepatology 42 2 301 309 16025511 10.1002/hep.20801 (Pubitemid 41061082)
53. JP Vartanian M Henry A Marchio R Suspene MM Aynaud D Guetard M Cervantes-Gonzalez C Battiston V Mazzaferro P Pineau A Dejean S Wain-Hobson 2010 Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis PLoS Pathog 6 5 e1000928 20523896 10.1371/journal.ppat.1000928
54. P Turelli B Mangeat S Jost S Vianin D Trono 2004 Inhibition of hepatitis B virus replication by APOBEC3G Science 303 5665 1829 15031497 10.1126/science.1092066 (Pubitemid 38374868)
55. Y Kamatani S Wattanapokayakit H Ochi T Kawaguchi A Takahashi N Hosono M Kubo T Tsunoda N Kamatani H Kumada A Puseenam T Sura Y Daigo K Chayama W Chantratita Y Nakamura K Matsuda 2009 A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians Nat Genet 41 5 591 595 19349983 10.1038/ng.348 1:CAS:528:DC%2BD1MXktVKgur4%3D
56. GK Lau D Ye 2010 Novel insights into the association between HLA-DP variants and persistent hepatitis B virus infection: a genome-wide association study Gastroenterology 138 1 394 396 19932209 10.1053/j.gastro.2009.11.030
57. T Pollicino L Belloni G Raffa N Pediconi G Squadrito G Raimondo M Levrero 2006 Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones Gastroenterology 130 3 823 837 16530522 10.1053/j.gastro.2006.01.001 1:CAS:528:DC%2BD28XjsVyltrs%3D (Pubitemid 43374531)
58. KA Zimmerman KP Fischer MA Joyce DL Tyrrell 2008 Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture J Virol 82 16 8013 8021 18524822 10.1128/JVI.00366-08 1:CAS:528:DC%2BD1cXpsVOqurg%3D
59. D Durantel C Alotte F Zoulim 2007 Glucosidase inhibitors as antiviral agents for hepatitis B and C Curr Opin Investig Drugs 8 2 125 129 17328228 1:CAS:528:DC%2BD2sXjt1Sgs7c%3D (Pubitemid 46438466)
60. A Mehta S Carrouee B Conyers R Jordan T Butters RA Dwek TM Block 2001 Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications Hepatology 33 6 1488 1495 11391538 10.1053/jhep.2001.25103 1:CAS:528:DC%2BD3MXktlygtLs%3D (Pubitemid 32496986)
61. SJ Stray CR Bourne S Punna WG Lewis MG Finn A Zlotnick 2005 A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly Proc Natl Acad Sci USA 102 23 8138 8143 15928089 10.1073/pnas. 0409732102 1:CAS:528:DC%2BD2MXlsV2msbc%3D (Pubitemid 40800056)
62. C Bourne S Lee B Venkataiah A Lee B Korba MG Finn A Zlotnick 2008 Small-molecule effectors of hepatitis B virus capsid assembly give insight into virus life cycle J Virol 82 20 10262 10270 18684823 10.1128/JVI.01360-08 1:CAS:528:DC%2BD1cXht1amtrjE
63. X Zhu G Zhao X Zhou X Xu G Xia Z Zheng L Wang X Yang S Li 2010 2,4-Diaryl-4,6,7,8-tetrahydroquinazolin-5(1H)-one derivatives as anti-HBV agents targeting at capsid assembly Bioorg Med Chem Lett 20 1 299 301 19897363 10.1016/j.bmcl.2009.10.119 1:CAS:528:DC%2BD1MXhsF2jsbzI
64. GY Wu XJ Zheng CC Yin D Jiang L Zhu Y Liu L Wei Y Wang HS Chen 2008 Inhibition of hepatitis B virus replication by Bay 41-4109 and its association with nucleocapsid disassembly J Chemother 20 4 458 467 18676226
65. SJ Stray A Zlotnick 2006 BAY 41-4109 has multiple effects on hepatitis B virus capsid assembly J Mol Recognit 19 6 542 548 17006877 10.1002/jmr.801 1:CAS:528:DC%2BD2sXhtVahu7s%3D (Pubitemid 46024897)
66. JJ Feld D Colledge V Sozzi R Edwards M Littlejohn SA Locarnini 2007 The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging Antiviral Res 76 2 168 177 17709147 10.1016/j.antiviral.2007.06. 014 1:CAS:528:DC%2BD2sXhtVOgtb3K (Pubitemid 47410321)
67. WE Delaney R Edwards D Colledge T Shaw P Furman G Painter S Locarnini 2002 Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro Antimicrob Agents Chemother 46 9 3057 3060 12183271 10.1128/AAC.46.9.3057-3060. 2002 1:CAS:528:DC%2BD38Xmtl2kurw%3D
68. YP Tseng YH Kuo CP Hu KS Jeng D Janmanchi CH Lin CK Chou SF Yeh 2008 The role of helioxanthin in inhibiting human hepatitis B viral replication and gene expression by interfering with the host transcriptional machinery of viral promoters Antiviral Res 77 3 206 214 18249449 10.1016/j.antiviral.2007.12.011 1:CAS:528:DC%2BD1cXhsl2htb0%3D
69. C Ying Y Li CH Leung MD Robek YC Cheng 2007 Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue Proc Natl Acad Sci USA 104 20 8526 8531 17488817 10.1073/pnas.0609883104 1:CAS:528:DC%2BD2sXmtVCgur4%3D (Pubitemid 47175521)
70. VR Anderson MP Curran 2007 Nitazoxanide: a review of its use in the treatment of gastrointestinal infections Drugs 67 13 1947 1967 17722965 10.2165/00003495-200767130-00015 1:CAS:528:DC%2BD2sXht1ajt77M (Pubitemid 47347408)
71. EB Keeffe JF Rossignol 2009 Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides World J Gastroenterol 15 15 1805 1808 19370775 10.3748/wjg.15.1805 1:CAS:528:DC%2BD1MXpsF2kur4%3D
72. M Elazar M Liu SA McKenna P Liu EA Gehrig JD Puglisi JF Rossignol JS Glenn 2009 The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation Gastroenterology 137 5 1827 1835 19664635 10.1053/j.gastro.2009.07.056 1:CAS:528:DC%2BD1MXhsVyhsbzF
73. BE Korba AB Montero K Farrar K Gaye S Mukerjee MS Ayers JF Rossignol 2008 Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication Antiviral Res 77 1 56 63 17888524 10.1016/j.antiviral.2007.08.005 1:CAS:528:DC%2BD1cXisFyltg%3D%3D
74. JF Rossignol EB Keeffe 2008 Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C Future Microbiol 3 539 545 18811238 10.2217/17460913.3.5.539 1:CAS:528:DC%2BD1cXhtFGlu7bK
75. I Zundorf T Dingermann 2009 siRNAs-your friend and helper? Pharm Unserer Zeit 38 1 9 11 19132657 10.1002/pauz.200890127
76. D Castanotto JJ Rossi 2009 The promises and pitfalls of RNA-interference-based therapeutics Nature 457 7228 426 433 19158789 10.1038/nature07758 1:CAS:528:DC%2BD1MXotlOgsA%3D%3D
77. D Sun C Rosler K Kidd-Ljunggren M Nassal 2010 Quantitative assessment of the antiviral potencies of 21 shRNA vectors targeting conserved, including structured, hepatitis B virus sites J Hepatol 52 6 817 826 20400195 10.1016/j.jhep.2009.10.038 1:CAS:528:DC%2BC3cXmsVejur0%3D
78. S Locarnini 2005 Therapies for hepatitis B: where to from here? Gastroenterology 128 3 789 792 15765416 10.1053/j.gastro.2005.01.017 (Pubitemid 40585383)
79. Y Ilan A Nagler R Adler R Tur-Kaspa S Slavin D Shouval 1993 Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor Gastroenterology 104 6 1818 1821 8500741 1:STN:280:DyaK3s3ntlajsQ%3D%3D (Pubitemid 23235477)
80. GK Lau AS Lok RH Liang CL Lai EK Chiu YL Lau SK Lam 1997 Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer Hepatology 25 6 1497 1501 9185774 10.1002/hep.510250631 1:STN:280:DyaK2szivFalsw%3D%3D (Pubitemid 27250775)
81. E Loggi F Bihl JV Chisholm 3rd M Biselli A Bontadini G Vitale G Ercolani GL Grazi AD Pinna M Bernardi C Brander P Andreone 2009 Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft J Hepatol 50 3 625 630 19157623 10.1016/j.jhep.2008.08.026
82. A Bertoletti A Gehring 2009 Therapeutic vaccination and novel strategies to treat chronic infection Expert Rev Gastroenterol Hepatol 3 5 561 569 19817676 10.1586/egh.09.48 1:CAS:528:DC%2BD1MXht1Cmt7nE
83. A Ciancio M Rizzetto 2010 Thymalfasin in the treatment of hepatitis B and C Ann NY Acad Sci 1194 141 146 20536462 10.1111/j.1749-6632.2010.05487.x 1:CAS:528:DC%2BC3cXntFyjtL0%3D
84. YY Zhang EQ Chen J Yang YR Duan H Tang 2009 Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis Virol J 6 63 19467157 10.1186/1743-422X-6-63
85. S Pol B Nalpas F Driss ML Michel P Tiollais J Denis C Brecho 2001 Efficacy and limitations of a specific immunotherapy in chronic hepatitis B J Hepatol 34 6 917 921 11451177 10.1016/S0168-8278(01)00028-9 1:CAS:528: DC%2BD3MXltlens7k%3D (Pubitemid 32595193)
86. P Vandepapeliere GK Lau G Leroux-Roels Y Horsmans E Gane T Tawandee MI Merican KM Win C Trepo G Cooksley M Wettendorff C Ferrari 2007 Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine Vaccine 25 51 8585 8597 18031872 10.1016/j.vaccine.2007.09.072 1:CAS:528:DC%2BD2sXhsVWjtr%2FO (Pubitemid 350192039)
87. F Rahman A Dahmen S Herzog-Hauff WO Bocher PR Galle HF Lohr 2000 Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen Hepatology 31 2 521 527 10655280 10.1002/hep.510310237 1:CAS:528:DC%2BD3cXht1aru7c%3D (Pubitemid 30078622)
88. MC Jung N Gruner R Zachoval W Schraut T Gerlach H Diepolder CA Schirren M Page J Bailey E Birtles E Whitehead J Trojan S Zeuzem GR Pape 2002 Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: Induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers Vaccine 20 29-30 3598 3612 12297407 10.1016/S0264-410X(02)00309-2 1:CAS:528:DC%2BD38Xnt1Cru7Y%3D (Pubitemid 35248086)
89. J Heathcote J McHutchison S Lee M Tong K Benner G Minuk T Wright J Fikes B Livingston A Sette R Chestnut 1999 A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group Hepatology 30 2 531 536 10421664 10.1002/hep.510300208 1:CAS:528:DyaK1MXlt1ajsLw%3D (Pubitemid 29357521)
90. A Vitiello G Ishioka HM Grey R Rose P Farness R LaFond L Yuan FV Chisari J Furze R Bartholomeuz, et al. 1995 Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans J Clin Invest 95 1 341 349 7814635 10.1172/JCI117662 1:CAS:528:DyaK2MXivFyksro%3D
91. SM Akbar H Murakami N Horiike M Onji 2004 Dendritic cell-based therapies in the bench and the bedsides Curr Drug Targets Inflamm Allergy 3 3 305 310 15379599 10.2174/1568010043343787 1:CAS:528:DC%2BD2cXmvVemur8%3D (Pubitemid 39206659)
92. DZ Xu K Zhao LM Guo LJ Li Q Xie H Ren JM Zhang M Xu HF Wang WX Huang XF Bai JQ Niu P Liu XY Chen XL Shen ZH Yuan XY Wang YM Wen 2008 A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients PLoS One 3 7 e2565 18596958 10.1371/journal.pone.0002565
93. X Yao B Zheng J Zhou DZ Xu K Zhao SH Sun ZH Yuan YM Wen 2007 Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients Vaccine 25 10 1771 1779 17224217 10.1016/j.vaccine.2006.11.019 1:CAS:528: DC%2BD2sXhtlarsLw%3D (Pubitemid 46188371)